Selecta Biosciences Inc. [NASDAQ: SELB] plunged by -$0.03 during the normal trading session on Tuesday and reaching a high of $2.83 during the day while it closed the day at $2.68. The company report on August 6, 2020 that Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates.
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR, today reported financial results for the second quarter ended June 30, 2020 and provided corporate updates.
“This is a transformational time for Selecta, as we reinforce our position as a leader in immune tolerance. The strategic licensing agreement with Sobi puts us in a financial position that allows us to maximize efforts to unlock the full potential of the ImmTOR immune tolerance platform, by optimizing the efficacy and safety of biologics, enabling re-dosing of life saving gene therapies, and creating novel immunotherapies for autoimmune diseases,” said Carsten Brunn, Ph.D., President and CEO of Selecta. “We remain committed to the development of SEL-212, and look forward to the initiation of the Phase 3 clinical program with Sobi in the third quarter of this year and the topline data readout from the Phase 2 COMPARE trial, also in the third quarter. We also look forward to advancing our gene therapy program in MMA to the clinic in the first half of 2021, and for the submission of an IND for our autoimmune diseases program, also in 2021.”.
Selecta Biosciences Inc. stock has also gained 2.29% of its value over the past 7 days. However, SELB stock has declined by -16.77% in the 3 months of the year. Over the past six months meanwhile, it has lost -39.91% and gained 12.61% year-on date.
The market cap for SELB stock reached $223.00 million, with 94.72 million shares outstanding and 73.07 million shares in the current float. Compared to the average trading volume of 2.41M shares, SELB reached a trading volume of 1094695 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Selecta Biosciences Inc. [SELB]:
Stifel have made an estimate for Selecta Biosciences Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on June 12, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on April 28, 2020, representing the official price target for Selecta Biosciences Inc. stock. Previously, the target price had yet another raise to $10, while Cantor Fitzgerald analysts kept a Overweight rating on SELB stock.
The Average True Range (ATR) for Selecta Biosciences Inc. is set at 0.19, with the Price to Sales ratio for SELB stock in the period of the last 12 months amounting to 33.28.
SELB stock trade performance evaluation
Selecta Biosciences Inc. [SELB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.29. With this latest performance, SELB shares gained by 13.08% in over the last four-week period, additionally sinking by -39.91% over the last 6 months – not to mention a rise of 54.02% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SELB stock in for the last two-week period is set at 52.21, with the RSI for the last a single of trading hit 52.90, and the three-weeks RSI is set at 48.68 for Selecta Biosciences Inc. [SELB]. The present Moving Average for the last 50 days of trading for this stock 2.87, while it was recorded at 2.67 for the last single week of trading, and 2.71 for the last 200 days.
Selecta Biosciences Inc. [SELB]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Selecta Biosciences Inc. [SELB] shares currently have an operating margin of -785.61. Selecta Biosciences Inc.’s Net Margin is presently recorded at -828.97.
Return on Total Capital for SELB is now -240.39, given the latest momentum, and Return on Invested Capital for the company is -3,716.01. Return on Equity for this stock declined to -3,716.01, with Return on Assets sitting at -76.85. When it comes to the capital structure of this company, Selecta Biosciences Inc. [SELB] has a Total Debt to Total Equity ratio set at 229.57. Additionally, SELB Total Debt to Total Capital is recorded at 69.66, with Total Debt to Total Assets ending up at 19.36.
Reflecting on the efficiency of the workforce at the company, Selecta Biosciences Inc. [SELB] managed to generate an average of -$1,419,231 per employee. Receivables Turnover for the company is 2.67 with a Total Asset Turnover recorded at a value of 0.09.Selecta Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.50 and a Current Ratio set at 2.50.
Earnings per share (EPS) analysis for Selecta Biosciences Inc. [SELB] stock
With the latest financial reports released by the company, Selecta Biosciences Inc. posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.33/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 21.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SELB.
Selecta Biosciences Inc. [SELB]: Insider Ownership positions
There are presently around $152 million, or 65.30% of SELB stock, in the hands of institutional investors. The top three institutional holders of SELB stocks are: VIVO CAPITAL, LLC with ownership of 7,846,509, which is approximately -9.018% of the company’s market cap and around 0.20% of the total institutional ownership; MANGROVE PARTNERS, holding 5,548,857 shares of the stock with an approximate value of $14.87 million in SELB stocks shares; and ECOR1 CAPITAL, LLC, currently with $12.32 million in SELB stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Selecta Biosciences Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 55 institutional holders increased their position in Selecta Biosciences Inc. [NASDAQ:SELB] by around 11,818,252 shares. Additionally, 16 investors decreased positions by around 3,929,679 shares, while 9 investors held positions by with 41,102,796 shares. The mentioned changes placed institutional holdings at 56,850,727 shares, according to the latest SEC report filing. SELB stock had 35 new institutional investments in for a total of 7,724,376 shares, while 9 institutional investors sold positions of 808,282 shares during the same period.